Open Access

CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas

  • Authors:
    • Kentaro Nakayama
    • Mohammed Tanjimur Rahman
    • Munmun Rahman
    • Kohei Nakamura
    • Masako Ishikawa
    • Hiroshi Katagiri
    • Emi Sato
    • Tomoka Ishibashi
    • Kouji Iida
    • Noriyuki Ishikawa
    • Satoru Kyo
  • View Affiliations

  • Published online on: November 26, 2015     https://doi.org/10.3892/ijo.2015.3268
  • Pages: 506-516
  • Copyright: © Nakayama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The clinicopathological significance of amplification was investigated of the gene encoding cyclin E (CCNE1) and we assessed whether CCNE1 was a potential target in endometrioid endometrial carcinomas. CCNE1 amplification and CCNE1 or F-box and WD repeat domain-containing 7 (FBXW7) expression in endometrial endometrioid carcinoma was assessed by immunohistochemistry and fluorescence in situ hybridization. CCNE1 knockdown by small interfering RNA (siRNA) was used to assess the CCNE1 function. The results showed that CCNE1 amplification was present in 9 (8.3%) of 108 endometrial carcinomas. CCNE1 amplification was correlated with high histological grade (Grade 3; p=0.0087) and lymphovascular space invasion (p=0.0258). No significant association was observed between CCNE1 amplification and FIGO stage (p=0.851), lymph node metastasis (p=0.078), body mass index (p=0.265), deep myometrial invasion (p=0.256), menopausal status (p=0.289) or patient age (p=0.0817). CCNE1 amplification was significantly correlated with shorter progression-free and overall survival (p=0.0081 and 0.0073, respectively). CCNE1 protein expression or loss of FBXW7 expression in endometrial endometrioid carcinoma tended to be correlated with shorter progression-free and overall survival; however, this difference was not statistically significant. Multivariate analysis showed that CCNE1 amplification was an independent prognostic factor for overall survival but not for progression-free survival (P=0.0454 and 0.2175, respectively). Profound growth inhibition was observed in siRNA-transfected cancer cells with endogenous CCNE1 overexpression compared with that in cancer cells having low CCNE1 expression. CCNE1 amplification was independent of p53, HER2, MLH1 and ARID1A expression but dependent on PTEN expression in endometrial carcinomas. These findings indicated that CCNE1 amplification was critical for the survival of endometrial endometrioid carcinomas. Furthermore, the effects of CCNE1 knockdown were dependent on the CCNE1 expression status, suggesting that CCNE1-targeted therapy may be beneficial for patients with endometrial endometrioid carcinoma having CCNE1 amplification.

References

1 

Pisani P, Bray F and Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 97:72–81. 2002. View Article : Google Scholar : PubMed/NCBI

2 

Akhmedkhanov A, Zeleniuch-Jacquotte A and Toniolo P: Role of exogenous and endogenous hormones in endometrial cancer: Review of the evidence and research perspectives. Ann NY Acad Sci. 943:296–315. 2001. View Article : Google Scholar : PubMed/NCBI

3 

Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P and Prat J: Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol. 32:569–577. 2001. View Article : Google Scholar : PubMed/NCBI

4 

Shiozawa T and Konishi I: Early endometrial carcinoma: Clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. Int J Clin Oncol. 11:13–21. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 57:3935–3940. 1997.PubMed/NCBI

6 

Oda K, Stokoe D, Taketani Y and McCormick F: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65:10669–10673. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, et al: Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 104:1503–1513. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Welcker M and Clurman BE: FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 8:83–93. 2008. View Article : Google Scholar

9 

Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M and Reed SI: hCDC4 gene mutations in endometrial cancer. Cancer Res. 62:4535–4539. 2002.PubMed/NCBI

10 

Knuutila S, Aalto Y, Autio K, Björkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, et al: DNA copy number losses in human neoplasms. Am J Pathol. 155:683–694. 1999. View Article : Google Scholar : PubMed/NCBI

11 

Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O and Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature. 413:316–322. 2001. View Article : Google Scholar : PubMed/NCBI

12 

Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Ishida N, Okumura F, Nakayama K and Nakayama KI: Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23:2116–2125. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Izumi N, Helker C, Ehling M, Behrens A, Herzog W and Adams RH: Fbxw7 controls angiogenesis by regulating endothelial Notch activity. PLoS One. 7:e411162012. View Article : Google Scholar : PubMed/NCBI

14 

Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al: SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 471:104–109. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, Kuwano H, Nakayama KI and Mori M: p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 69:3788–3794. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Debies MT and Welch DR: Genetic basis of human breast cancer metastasis. J Mammary Gland Biol Neoplasia. 6:441–451. 2001. View Article : Google Scholar

17 

Albertson DG, Collins C, McCormick F and Gray JW: Chromosome aberrations in solid tumors. Nat Genet. 34:369–376. 2003. View Article : Google Scholar : PubMed/NCBI

18 

Wang TL, Diaz LA Jr, Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IeM, et al: Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci USA. 101:3089–3094. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Mao TL, Seidman JD, Kurman RJ and Shih IeM: Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor--an aid in differential diagnosis. Am J Surg Pathol. 30:1105–1110. 2006. View Article : Google Scholar : PubMed/NCBI

20 

Rahman M, Nakayama K, Rahman MT, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K and Miyazaki K: Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. Hum Pathol. 44:103–109. 2013. View Article : Google Scholar

21 

Rahman MT, Nakayama K, Ishikawa M, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K and Miyazaki K: Fatty acid synthase is a potential therapeutic target in estrogen receptor-/ progesterone receptor-positive endometrioid endometrial cancer. Oncology. 84:166–173. 2013. View Article : Google Scholar

22 

Nakayama K, Miyazaki K, Kanzaki A, Fukumoto M and Takebayashi Y: Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep. 8:1285–1287. 2001.PubMed/NCBI

23 

Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Kato N, Watanabe J, Jobo T, Nishimura Y, Fujisawa T, Kamata Y and Kuramoto H: Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol. 129:222–226. 2003.PubMed/NCBI

25 

Scott M and Hall PA: Prognostic and predictive factors. Methods Mol Med. 97:1–11. 2004.PubMed/NCBI

26 

Hwang HC and Clurman BE: Cyclin E in normal and neoplastic cell cycles. Oncogene. 24:2776–2786. 2005. View Article : Google Scholar : PubMed/NCBI

27 

Geng Y, Lee YM, Welcker M, Swanger J, Zagozdzon A, Winer JD, Roberts JM, Kaldis P, Clurman BE and Sicinski P: Kinase-independent function of cyclin E. Mol Cell. 25:127–139. 2007. View Article : Google Scholar : PubMed/NCBI

28 

Cassia R, Moreno-Bueno G, Rodríguez-Perales S, Hardisson D, Cigudosa JC and Palacios J: Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol. 201:589–595. 2003. View Article : Google Scholar : PubMed/NCBI

29 

Santala S, Talvensaari-Mattila A, Soini Y and Santala M: Cyclin E expression correlates with cancer-specific survival in endometrial endometrioid adenocarcinoma. Anticancer Res. 35:3393–3397. 2015.PubMed/NCBI

30 

Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K and Miyazaki K: Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer. 116:2621–2634. 2010.PubMed/NCBI

31 

Pelengaris S and Khan M: The many faces of c-MYC. Arch Biochem Biophys. 416:129–136. 2003. View Article : Google Scholar : PubMed/NCBI

32 

Kubben FJ, Sier CF, van Duijn W, Griffioen G, Hanemaaijer R, van de Velde CJ, van Krieken JH, Lamers CB and Verspaget HW: Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer. 94:1035–1040. 2006. View Article : Google Scholar : PubMed/NCBI

33 

Calcagno DQ, Freitas VM, Leal MF, de Souza CR, Demachki S, Montenegro R, Assumpção PP, Khayat AS, Smith MA, dos Santos AK, et al: MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. BMC Gastroenterol. 13:1412013. View Article : Google Scholar : PubMed/NCBI

34 

Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R and Balmain A: FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 321:1499–1502. 2008. View Article : Google Scholar : PubMed/NCBI

35 

Tu K, Zheng X, Zan X, Han S, Yao Y and Liu Q: Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma. Hepatol Res. 42:904–910. 2012. View Article : Google Scholar : PubMed/NCBI

36 

Ibusuki M, Yamamoto Y, Shinriki S, Ando Y and Iwase H: Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci. 102:439–445. 2011. View Article : Google Scholar

37 

Mitsuhashi Y, Horiuchi A, Miyamoto T, Kashima H, Suzuki A and Shiozawa T: Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells. Histopathology. 60:826–837. 2012. View Article : Google Scholar : PubMed/NCBI

38 

Peiró G, Peiró FM, Ortiz-Martínez F, Planelles M, Sánchez-Tejada L, Alenda C, Ceballos S, Sánchez-Payá J and Laforga JB: Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: A potential target treatment. Hum Pathol. 44:218–225. 2013. View Article : Google Scholar

39 

Okuda T, Sekizawa A, Purwosunu Y, Nagatsuka M, Morioka M, Hayashi M and Okai T: Genetics of endometrial cancers. Obstet Gynecol Int. 2010:9840132010. View Article : Google Scholar : PubMed/NCBI

40 

Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X and Matias-Guiu X: Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol. 62:777–785. 2009. View Article : Google Scholar

41 

Ioffe OB, Papadimitriou JC and Drachenberg CB: Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol. 29:1150–1159. 1998. View Article : Google Scholar : PubMed/NCBI

42 

Sherman ME, Bur ME and Kurman RJ: p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis. Hum Pathol. 26:1268–1274. 1995. View Article : Google Scholar : PubMed/NCBI

43 

Weinstein IB, Joe A and Felsher D: Oncogene addiction. Cancer Res. 68:3077–3080; discussion 3080. 2008. View Article : Google Scholar : PubMed/NCBI

44 

Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, et al: Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol. 16:158–161. 2005. View Article : Google Scholar

45 

Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, Huitema AD, Norbury CJ, Ellis P, Bosquee L, et al: A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 13:1816–1822. 2007. View Article : Google Scholar : PubMed/NCBI

46 

Nakayama K, Nakayama N, Ishikawa M and Miyazaki K: Endometrial serous carcinoma: Its molecular characteristics and histology-specific treatment strategies. Cancers (Basel). 4:799–807. 2012. View Article : Google Scholar

47 

Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, et al: KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer. 107:1997–2004. 2012. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February 2016
Volume 48 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakayama, K., Rahman, M.T., Rahman, M., Nakamura, K., Ishikawa, M., Katagiri, H. ... Kyo, S. (2016). CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas. International Journal of Oncology, 48, 506-516. https://doi.org/10.3892/ijo.2015.3268
MLA
Nakayama, K., Rahman, M. T., Rahman, M., Nakamura, K., Ishikawa, M., Katagiri, H., Sato, E., Ishibashi, T., Iida, K., Ishikawa, N., Kyo, S."CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas". International Journal of Oncology 48.2 (2016): 506-516.
Chicago
Nakayama, K., Rahman, M. T., Rahman, M., Nakamura, K., Ishikawa, M., Katagiri, H., Sato, E., Ishibashi, T., Iida, K., Ishikawa, N., Kyo, S."CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas". International Journal of Oncology 48, no. 2 (2016): 506-516. https://doi.org/10.3892/ijo.2015.3268